Introduction {#Sec1}
============

There has been a dramatic increase in the incidence of obesity and overweight worldwide^[@CR1]^. As a result, in western countries up to 60% of women of reproductive age are either overweight or obese^[@CR2],\ [@CR3]^, and gestational diabetes affects up to 12% of pregnancies^[@CR4]^.

Maternal pre-pregnancy obesity is associated with adverse changes in body composition in the offspring including macrosomia (and occasionally intrauterine growth retardation), greater adiposity in childhood, and obesity in later life, thus perpetuating a vicious cycle of metabolic disorders across generations^[@CR5],\ [@CR6]^. Maternal obesity appears to be the strongest predictor of offspring obesity^[@CR7]^, and even outside the obese range increasing pre-pregnancy body mass index is associated with greater adiposity and an adverse metabolic phenotype in the offspring^[@CR8]^. This includes lower insulin sensitivity, an unfavourable adipokine profile, increased blood pressure and triglyceride concentrations^[@CR9],\ [@CR10]^ and increased risk of type 2 diabetes and the metabolic syndrome^[@CR11]^. While the mechanisms remain unclear, the adverse effects seen in the offspring appear to be mediated (at least in part) by exaggeration of the normal insulin resistance of pregnancy. This leads to excess delivery of glucose and fatty acids to the fetus^[@CR12]^, and ultimately to lifelong alterations in gene expression through epigenetic changes^[@CR13]^.

Adverse metabolic programming of offspring as a consequence of a maternal obesogenic environment has important implications for our increasingly overweight society. The origins of the obesity epidemic may lie in a postnatal environment characterized by abundance of high-energy foods and an increasingly sedentary lifestyle. However, now that obesity is common, a second factor has emerged: the transgenerational perpetuation of obesity and metabolic disease through maternal obesity and insulin resistance^[@CR14]^. This highlights pregnancy as a critical early window of opportunity where treatments that reduce fetal overnutrition may have lifelong benefit^[@CR14]^, potentially improving insulin sensitivity and in turn reducing the risk of type 2 diabetes and cardiovascular disease^[@CR15]^.

In rodent pregnancy, insulin resistance is readily induced by a high-fat diet rich in saturated fat^[@CR16]--[@CR18]^, which also leads to an offspring phenotype of leptin resistance with hyperphagia^[@CR19],\ [@CR20]^, increased body weight and adiposity^[@CR16],\ [@CR17],\ [@CR20]^, reduced insulin sensitivity^[@CR16],\ [@CR20]^, dyslipidaemia^[@CR20]^, and elevated blood pressure^[@CR17],\ [@CR20]^. This phenotype is similar to the offspring of insulin resistant women^[@CR8],\ [@CR11]^. The long-term metabolic effects of altering maternal consumption of polyunsaturated fatty acids are not well defined. However, studies have shown that: (a) greater consumption of omega-6 polyunsaturated fatty acids (n-6 PUFAs) is associated with greater adiposity in the offspring^[@CR21]^, (b) increasing omega-3 (n-3) PUFA consumption may reduce offspring adiposity^[@CR22]^, and (c) a diet deficient in n-3 PUFAs leads to abnormalities of appetite regulation^[@CR23]^. The ratio of n-6:n-3 PUFAs also appears to be important, and this is probably because n-3 and n-6 PUFAs compete at key enzymes for elongation and production of active metabolites^[@CR24]^.

n-3 PUFAs have anti-inflammatory and insulin-sensitising effects that could make them a useful treatment to prevent the long-term effects of maternal insulin resistance in the offspring. In non-pregnant rodents, insulin resistance can be prevented by supplementation with fish oil^[@CR25],\ [@CR26]^, an effect mediated by the anti-inflammatory effects of n-3 PUFAs in adipose tissue^[@CR25]^. Recent evidence suggests that n-3 PUFA supplementation is also insulin-sensitising in humans^[@CR27],\ [@CR28]^, and that supplementation in obese pregnant women reduces adipose tissue inflammation^[@CR29]^. These observations raise the possibility that fish oil supplementation in pregnancy could prevent metabolic dysfunction in the offspring of insulin-resistant women. Thus, we utilised an established rat model of high-fat feeding in pregnancy to test the primary hypothesis that maternal fish oil supplementation in pregnancy would prevent the development of insulin resistance in the offspring. In addition, we aimed to assess the effects of the fish oil intervention on body composition and other metabolic markers in the adult offspring.

Methods {#Sec2}
=======

Animal Ethics {#Sec3}
-------------

Ethics approval was granted by the Auckland University Animal Ethics Committee (approval \#001175). This study was performed in accordance with all appropriate institutional and international guidelines and regulations for animal research.

Study design {#Sec4}
------------

A model of maternal obesity was utilised as previously reported by our group, in which a maternal high-fat diet leads to increased body fat in the offspring and results in fasting hyperinsulinaemia and hyperleptinaemia (compared with rats exposed to a standard maternal diet), independently of postnatal diet^[@CR16]^. Fifty-two virgin female Sprague-Dawley rats (age 110 days) were assigned to one of two isocaloric diets *ad libitum* for ten days prior to mating: a high-fat diet (HF, D12451, Research Diets Inc, New Brunswick, NJ USA) which contained 45% kcal as fat, or a matched control diet (D12450H) containing 10% kcal as fat (Table [1](#Tab1){ref-type="table"}). Rats were time-mated using an oestrous cycle monitor (EC-40, Fine Science Tools, San Francisco, CA, USA). Day 1 of pregnancy was determined by detection of spermatozoa by vaginal lavage, and dams were individually housed and continued on their respective study diet. On Day 1 of pregnancy, dams were further allocated to one of two treatment groups: fish oil (FO) or water (control). On each day of pregnancy, 1 ml of the treatment was administered by gavage. Thus, there were four treatment groups: (1) Con-Con, where dams consumed a control diet and had water by gavage; (2) Con-FO, where dams consumed a control diet and had fish oil by gavage; (3) HF-Con, where dams consumed a high-fat diet and had water by gavage; and (4) HF-FO, where dams had high-fat diet and fish oil by gavage (Fig. [1](#Fig1){ref-type="fig"}). Importantly, as dams from all groups underwent daily gavage, any potential stressful effects related to the gavage procedure were controlled for.Table 1Nutritional content of control and high-fat diets given to rat dams during pregnancy and lactation.MacronutrientDescriptionUnitControl diet (D12450H)High-fat diet (D12451)ProteinTotal% kcal2020CarbohydrateSucrose% kcal1717Other carbohydrates% kcal5318FatTotal% kcal1045Saturated fats% of total fat (wt)22.731.4Monounsaturated fats% of total fat (wt)29.935.5Polyunsaturated fats% of total fat (wt)47.433.1Eicosapentaenoic acid (EPA)% of total fat (wt)00Docosahexaenoic acid (DHA)% of total fat (wt)00Data have been provided by the manufacturer (Research Diets Inc.). Figure 1Diagram describing individual steps of the trial and indicating the timing of assessments. T1: Virgin female rats were randomised to control or high-fat diet. T2: Females were mated and further randomised to one of the two gavage treatments, i.e. Fish oil or Control (water). T3: on postnatal day 2 pups were counted, sexed and weighed; excess pups were culled. T4: on postnatal day 21 pups were separated, while dams were culled and had samples taken. T5: final metabolic assessments of adult male offspring.

The treatment oil was derived from hoki (*Macruronus novaezelandiae*) liver (Seadragon Marine Oils, Nelson, New Zealand). We independently verified n-3 PUFA content (Table [2](#Tab2){ref-type="table"}) and the oxidative state, using methodology previously described^[@CR30]^. The oil had very low levels of oxidation, with a peroxide value of 2.7 meq/kg and anisidine value of 0.6 at the start of the study, well within international recommendations^[@CR31]^ and below all products tested in a recent study of fish oil products available for purchase in the New Zealand market^[@CR30]^. At the end of the study, the oil remained unoxidised, with a peroxide value of 3.1 meq/kg and ansidine value of 0.9. One ml/day of fish oil equated to a daily dose of 39 mg eicosapentaenoic acid (EPA) and 82 mg docosahexaenoic acid (DHA). To ensure standardised dosage and to prevent inadvertent oxidation, delivery of the treatment (oil or water) was administered by oral gavage. In addition, the fish oil was stored in small aliquots, frozen, sealed, and kept in darkness, so that each day a new aliquot was thawed prior to use, minimizing any oxidation of the oil. Minimising the risk of oxidation is important, as in a parallel study we demonstrated that feeding highly oxidised fish oil (peroxide value 48.8 meq/kg, anisidine value 4.5) to rat dams led to maternal insulin resistance and a substantial increase in neonatal mortality^[@CR32]^.Table 2Fatty acid concentrations in the fish oil supplement (mg/g of oil), determined by gas chromatography.Fatty acidConcentrationC16:0 (palmitic acid)105.53 ± 4.92C16:1n-7 (palmitoleic acid)15.86 ± 0.84C18:0 (stearic acid)28.26 ± 1.37C18:1n-7 (cis-vaccenic acid)4.35 ± 0.12C18:1n-9 (oleic acid)425.59 ± 19.58C18:2n-6 (linoleic acid)3.12 ± 0.09C18:3n-3 (α-linolenic acid)5.52 ± 0.13C18:3n-6 (γ-linolenic acid)1.68 ± 0.59C20:0 (arachidic acid)0.72 ± 0.03C20:1n-9 (eicosenoic acid)0.47 ± 0.03C20:2n-6 (eicosadienoic acid)1.67 ± 0.08C20:3n-6 (dihomo-γ-linolenic acid)4.10 ± 0.27C20:4n-6 (arachidonic acid)2.90 ± 0.19C20:5n-3 (eicosapentaenoic acid)42.53 ± 1.85C22:5n-3 (docosapentaenoic acid)1.09 ± 0.08C22:6n-3 (docosahexaenoic acid)89.00 ± 4.34Data are means ± standard deviations, from analysis of 6 replicates.

Maternal food intake and body weight were recorded every 3^rd^ day. At birth, the gavage treatment was stopped, but the same diets were maintained *ad libitum* throughout lactation. Offspring were counted, sexed (by measuring anogenital distance), weighed and measured on postnatal day 2. On this day, litter size was also randomly adjusted to 8 pups to ensure standardized nutrition until weaning. The primary aim of this study was to assess metabolic phenotype in adult male offspring to avoid the confounding effect of oestrous on insulin sensitivity, thus 6 males and 2 females were kept. Pups not allocated to litters were killed by decapitation, when plasma, red blood cells, liver, and heart were collected. Pups were weighed every 3^rd^ day until the time of weaning (day 21), when they were housed in pairs for the remainder of the study (until day 110). All offspring were fed a standard chow diet (Harlan-Teklad Diet 2018, Oxon, UK) *ad libitum*, with food intakes and body weights recorded every 3^rd^ day.

From the adult offspring within each of the 4 treatment groups, 12 animals were randomly selected for metabolic assessment.

At postnatal day 90, body composition was quantified using dual x-ray absorptiometry (DXA, Lunar Prodigy 2000, General Electric, Madison, USA), while animals were under light isoflurane anaesthesia.

Systolic blood pressure was analysed at 95 days of age by tail cuff plethysmography (Model 179 with an automatic cuff inflation pump (NW20), IITC, Life Science, Woodland Hills, CA), according to the manufacturer's instructions as previously described^[@CR33]^. Adult offspring were warmed using a heat lamp and acclimatised to the restraint tube for 15 minutes prior to blood pressure recordings. Three clear pressure recordings were taken per animal (CV \< 5%) and mean blood pressure calculated.

At day 100, insulin sensitivity was assessed by an oral glucose tolerance test following a 6-hour fast. After collection of tail blood (at T0), a glucose load (1 g/kg of body weight) was given by gavage. Blood was collected from the tail at T30, T60, T90 and T120 minutes. Glucose was measured at each time point, with plasma insulin also measured at T0, T30, T60, T90 and T120. Insulin and glucose concentrations were used to derive the Matsuda index of insulin sensitivity^[@CR34]^, which was the primary outcome of this study. The Matsuda index of insulin sensitivity has been shown to be closely correlated to the hyperinsulinaemic euglycaemic clamp (r = 0.77)^[@CR35]^. Its use in rats has been recently described^[@CR36]^. In addition, we also calculated HOMA-IR, which is a fasting index of insulin resistance well correlated to the hyperinsulinaemic euglycaemic clamp (r = 0.7)^[@CR37]^ and widely reported in rats, as well as glucose and insulin area under the curve (AUC) using the trapezoidal method.

Terminal sample collection {#Sec5}
--------------------------

At day 110, adult offspring were fasted overnight and killed by sodium pentobarbitone anaesthesia (60 mg/kg; intraperitoneal) followed by decapitation. Blood was collected in EDTA tubes and stored on ice until centrifugation and removal of plasma for analysis. Liver and the retroperitoneal and gonadal fat pads were harvested and weighed.

Assays {#Sec6}
------

During the oral glucose tolerance test, glucose concentration was measured by glucometer (Optium Xceed; Abbott Laboratories) from tail whole blood, at the time samples were taken. Insulin and leptin concentrations were measured by ELISA (Crystal Chem, Illinois, USA) with CVs of 11% and 7%, respectively. Glucose, creatinine, alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate transaminase (AST), free fatty acids, uric acid, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and total cholesterol were measured on a Hitachi 902 autoanalyser (Hitachi High Technologies Corporation, Tokyo, Japan) with all CVs less than 6%.

Primary outcome and power analysis {#Sec7}
----------------------------------

The primary outcome of this study was the Matsuda index of insulin sensitivity in the adult male offspring. Two major comparisons were required: 1) HF-Con vs Con-Con to show the effect of the high-fat diet in pregnancy and lactation, and 2) HF-FO vs HF-Con to show the additional effect of further supplementation with fish oil to dams consuming a high-fat diet. Due to limited data regarding the standard deviation of the Matsuda index in rats, sample size was calculated to enable differences to be shown in fasting insulin. Given previous data showing maternal high-fat diet was associated with a mean fasting insulin of 4.89 ng/ml and standard deviation of 0.926 in the adult male offspring^[@CR16]^, a sample of approximately 12 animals per group was required to have 90% power to detect a 25% change in fasting insulin.

Statistical analyses {#Sec8}
--------------------

Outcomes in rat dam were compared using general linear regression models, with diet and gavage included as factors. Offspring outcomes were assessed using linear mixed models, including dam identification code as a random factor. The interaction between diet and gavage was examined in all models. Differences in weight, food and energy consumption in dams and offspring over time were compared using multiple t tests and Holm-Sidak correction for multiple comparisons. All statistical analyses were carried out in SAS v.9.4 (SAS Institute, Cary, NC, USA), except t tests which were carried out in Prism v.6.03 (Graphpad Software Inc, La Jolla, CA, USA). All tests were two-tailed with significance level maintained at 5%.

Results {#Sec9}
=======

Of the 52 rat dams mated, 34 became pregnant and successfully had pups (Table [3](#Tab3){ref-type="table"}). Neither diet, nor gavage treatment affected the number of offspring per litter (Table [3](#Tab3){ref-type="table"}).Table 3Maternal weight and metabolic parameters at key milestones of the study and litter characteristics at birth, according to the maternal diet (control or high-fat) and the gavage treatment during pregnancy \[fish oil or control (water)\].Maternal control dietMaternal high-fat dietControlFish oilControlFish oiln8998Maternal weight (g)  Prior to diet allocation (day -10)301 ± 6298 ± 10296 ± 5303 ± 6  Mating (day 1)310 ± 7307 ± 10322 ± 7332 ± 12  End of pregnancy (day 22)434 ± 6444 ± 14457 ± 16445 ± 17  End of lactation (day 40)342 ± 4359 ± 13368 ± 9^†^360 ± 11  Gestational weight gain40 ± 245 ± 242 ± 434 ± 3  Retroperitoneal fat (% of body weight at day 40)1.2 ± 0.21.3 ± 0.21.6 ± 0.1^†^1.2 ± 0.1^\#^Metabolic parameters (day 40)  Fasting glucose (mmol/l)4.44 ± 0.174.56 ± 0.155.20 ± 0.32^†^4.93 ± 0.18  Fasting insulin (pmol/l)180 ± 19323 ± 118403 ± 91332 ± 58  HOMA-IR0.98 ± 0.091.84 ± 0.662.58 ± 0.58^‡^2.01 ± 0.37  Triglycerides (mmol/l)0.52 ± 0.030.47 ± 0.020.68 ± 0.05^†^0.72 ± 0.05Birth characteristics  Litter size (n)11.8 ± 1.014.1 ± 0.913.7 ± 0.811.9 ± 1.1  Sex ratio (% male per litter)45 ± 542 ± 457 ± 3^†^50 ± 4  Weight of pups (g)5.6 ± 0.35.6 ± 0.35.4 ± 0.26.2 ± 0.4\*  Length of pups (mm)47.7 ± 0.247.4 ± 0.246.7 ± 0.448.9 ± 0.2\*\*Data are means ± standard errors. ^‡^p \< 0.06 and ^†^p \< 0.05 for a maternal diet effect among controls; ^\#^p \< 0.06, \*p \< 0.05, and \*\*p \< 0.01 for an effect of the gavage treatment between groups exposed to the same maternal diet.

Effects of maternal high-fat diet {#Sec10}
---------------------------------

At the end of lactation, dams from the HF-Con group had similar energy intake to Con-Con dams, but had greater body weight (Fig. [2A](#Fig2){ref-type="fig"}) and retroperitoneal fat mass (Table [3](#Tab3){ref-type="table"}). This was associated with greater fasting glucose (p = 0.018) and triglyceride (p = 0.047) concentrations, as well as a trend to greater insulin resistance (i.e. higher HOMA-IR; p = 0.058) (Table [3](#Tab3){ref-type="table"}).Figure 2Weight, food consumption, and energy intake in rat dams (**A**) and male offspring (**B**) according to the maternal diet (control or high-fat) and gavaged treatment during pregnancy \[fish oil or control (water)\]. A: body weight (A1), food consumption (A2), and total energy consumption including diet and gavaged oil (A3) of dams from mating (day 0) through to weaning (day 40). B: body weight (B1), food consumption (B2), and cumulative food consumption of male offspring from weaning through to termination (day 110) (B3). Error bars represent standard errors; \*p \< 0.05 for a difference in weight between Con-Con and HF-Con groups across the life span; ^†^p \< 0.05 for a difference in food intake between Con-Con and HF-Con groups from day 60 when intake stabilized; ^‡^p \< 0.05 for a difference between Con-Con and HF-Con groups at termination.

HF-Con litters had a greater proportion of male pups than the Con-Con group (Table [3](#Tab3){ref-type="table"}). Male HF-Con offspring had greater food consumption and body weight (than in the Con-Con group), which were first detectable at postnatal day 57 (Fig. [2B](#Fig2){ref-type="fig"}). In the final assessments, adult males of the HF-Con group had greater body weight (+98 g; p = 0.030) and adiposity (+6.4% of body fat; p = 0.008), with proportionally greater retroperitoneal (+1.11%; p = 0.009) and gonadal (+0.63%; p = 0.002) fat compared with Con-Con males (Table [4](#Tab4){ref-type="table"}).Table 4Study outcomes among male offspring according to the maternal diet (control or high-fat) and the gavage treatment during pregnancy \[fish oil or control (water)\].TimeMaternal control dietMaternal high-fat dietControlFish oilControlFish oiln12121212Pubertal onset (days)43.3 ± 0.641.3 ± 0.643.4 ± 0.642.2 ± 0.5Auxology24 dWeaning weight (g)48 ± 354 ± 254 ± 361 ± 390 dTotal body fat (%)22.9 ± 1.124.2 ± 1.229.3 ± 1.0^††^27.0 ± 1.4Fat mass to lean mass ratio0.30 ± 0.020.32 ± 0.020.42 ± 0.02^††^0.38 ± 0.03Bone mineral density (g/cm^2^)0.154 ± 0.0020.156 ± 0.0020.158 ± 0.0020.161 ± 0.002108 dWeight (g)495 ± 19541 ± 15593 ± 22^†^593 ± 19Length (mm)258 ± 2258 ± 2266 ± 3262 ± 2110 dLiver weight (% body weight)2.85 ± 0.093.01 ± 0.063.01 ± 0.092.97 ± 0.07Gonadal fat (% body weight)1.77 ± 0.0112.15 ± 0.122.40 ± 0.13^††^2.27 ± 0.18Retroperitoneal fat (% body weight)1.98 ± 0.302.31 ± 0.163.09 ± 0.25^††^2.68 ± 0.21Diet108 dEnergy intake (kcal/day)85 ± 392 ± 2101 ± 3^†^95 ± 4Energy intake per body weight (kcal/g/day)0.17 ± 0.010.17 ± 0.010.17 ± 0.010.16 ± 0.01Cumulative food intake (g)705 ± 22751 ± 13794 ± 17^†^795 ± 31"Cumulative food intake" reflects the weight of all food consumed by an individual rat since weaning. Data are means ± standard errors. ^†^p \< 0.05 and ^††^p \< 0.01 for a maternal diet effect among the offspring of dams that received control gavage. Note that all study groups consisted of 5 to 7 separate litters. Time represents the age of the animals in days.

Importantly, the male adult HF-Con offspring had lower insulin sensitivity than the Con-Con rats, as indicated by a lower Matsuda index (−38%; p = 0.036), higher HOMA-IR (+51%; p = 0.042), and greater insulin AUC (+63%; p = 0.023) (Table [5](#Tab5){ref-type="table"}). This was accompanied by other markers of metabolic dysfunction, including higher systolic blood pressure (+12 mmHg, p \< 0.0001), and increased triglyceride (+0.55 mmol/l; p = 0.014) and leptin (+4.1 ng/ml; p = 0.002) concentrations (Table [5](#Tab5){ref-type="table"}). Thus, as expected^[@CR16]--[@CR20]^, maternal high-fat diet led to adverse programming of energy balance, body composition, and metabolism in adult male offspring.Table 5Study outcomes among adult male offspring according to the maternal diet (control or high-fat), and gavage treatment during pregnancy \[fish oil or control (water)\].Maternal control dietMaternal high-fat dietControlFish oilControlFish oiln12121212Glucose homeostasis  Matsuda index1.35 ± 0.171.27 ± 0.250.84 ± 0.09^†^1.55 ± 0.26\*  HOMA-IR3.02 ± 0.413.89 ± 0.634.57 ± 0.54^†^2.66 ± 0.42\*  Fasting glucose (mmol/l)4.96 ± 0.145.46 ± 0.215.03 ± 0.115.03 ± 0.21  Glucose AUC (min.mmol/l)847 ± 25841 ± 28866 ± 31818 ± 29  Fasting insulin (pmol/l)497 ± 63556 ± 74732 ± 79434 ± 71\*  Insulin AUC (x10^3^ min.pmol/l)76 ± 982 ± 11124 ± 14^†^81 ± 9Liver function  ALP (U/l)79 ± 466 ± 376 ± 582 ± 6  AST (U/l)144 ± 13133 ± 5171 ± 9160 ± 14  ALT (U/l)36 ± 235 ± 238 ± 438 ± 2Lipids  Free fatty acids (mmol/l)0.83 ± 0.090.79 ± 0.070.95 ± 0.120.83 ± 0.08  Total cholesterol (mmol/l)1.70 ± 0.131.94 ± 0.111.96 ± 0.151.81 ± 0.09  HDL-C (mmol/l)1.21 ± 0.091.46 ± 0.081.37 ± 0.101.39 ± 0.06  LDL-C (mmol/l)0.29 ± 0.030.25 ± 0.030.25 ± 0.020.25 ± 0.03  Triglycerides (mmol/l)0.68 ± 0.070.94 ± 0.091.23 ± 0.15^†^0.87 ± 0.11Other  Uric acid (µmol/l)71 ± 575 ± 273 ± 369 ± 6  Leptin (ng/ml)1.6 ± 0.34.2 ± 1.3\*5.7 ± 1.3^††^4.0 ± 0.9  Systolic blood pressure (mmHg)124 ± 1125 ± 1136 ± 1^††††^135 ± 1Data are means ± standard errors. ^†^p \< 0.05, ^††^p \< 0.01, and ^††††^p \< 0.0001 for a maternal diet effect among the offspring of dams that received control gavage; \*p \< 0.05 and \*\*p \< 0.01 for an effect of the gavage treatment between groups exposed to the same maternal diet. ALP -- alkaline phosphatase; ALT -- alanine transaminase; AST -- aspartate transaminase; AUC -- area under the curve; HDL-C -- high-density lipoprotein cholesterol; and LDL-C low-density lipoprotein cholesterol.

Effects of supplemental fish oil in the context of a maternal high-fat diet {#Sec11}
---------------------------------------------------------------------------

HF-FO dams were not different from HF-Con dams in terms of body weight, food intake, or total energy intake (Fig. [2A](#Fig2){ref-type="fig"}). There were no effects of fish oil supplementation on metabolic parameters measured (Table [3](#Tab3){ref-type="table"}). However, HF-FO pups were heavier and longer than HF-Con pups (Table [3](#Tab3){ref-type="table"}), and had 33% greater EPA concentration in liver phospholipid (Table [6](#Tab6){ref-type="table"}).Table 6Concentrations of polyunsaturated fatty acids in liver phospholipids of rat pups culled at day 2, according to the maternal diet (control or high-fat) and the gavage treatment during pregnancy \[fish oil or control (water)\].Maternal control dietMaternal high-fat dietControlFish oilControlFish oiln912178C16:0 (palmitic acid)24.49 ± 1.0624.41 ± 1.0823.21 ± 0.5824.13 ± 0.50C16:1n-7 (palmitoleic acid)1.32 ± 0.091.26 ± 0.070.70 ± 0.05^††††^0.65 ± 0.05C18:0 (stearic acid)16.61 ± 1.0416.19 ± 0.8817.06 ± 0.6115.53 ± 0.86C18:1n-7 (cis-vaccenic acid)1.87 ± 0.161.95 ± 0.111.61 ± 0.101.33 ± 0.08C18:1n-9 (oleic acid)9.67 ± 0.589.60 ± 0.4810.47 ± 0.639.47 ± 1.00C18:2n-6 (linoleic acid)10.74 ± 0.4010.45 ± 0.6511.13 ± 0.3511.39 ± 0.39C18:3n-3 (α-linolenic acid)0.23 ± 0.040.25 ± 0.030.19 ± 0.020.24 ± 0.02C18:3n-6 (γ-linolenic acid)0.44 ± 0.060.35 ± 0.030.36 ± 0.030.43 ± 0.048C20:0 (arachidic acid)0.62 ± 0.070.52 ± 0.060.60 ± 0.050.61 ± 0.06C20:1n-9 (eicosenoic acid)0.21 ± 0.030.28 ± 0.030.20 ± 0.010.26 ± 0.03C20:2n-6 (eicosadienoic acid)0.73 ± 0.050.72 ± 0.040.60 ± 0.03^†^0.61 ± 0.06C20:3n-6 (dihomo-γ-linolenic acid)0.75 ± 0.090.71 ± 0.060.85 ± 0.060.81 ± 0.10C20:4n-6 (arachidonic acid)17.57 ± 0.9718.57 ± 1.2518.84 ± 0.7618.42 ± 0.60C20:5n-3 (eicosapentaenoic acid)0.65 ± 0.070.66 ± 0.050.51 ± 0.040.68 ± 0.05\*\*C22:4n-6 (adrenic acid)4.06 ± 0.573.56 ± 0.463.37 ± 0.294.21 ± 0.23C22:5n-6 (n-6 docosapentaenoic acid)1.46 ± 0.291.39 ± 0.161.27 ± 0.110.19 ± 0.13C22:5n-3 (n-3 docosapentaenoic acid)4.71 ± 0.315.03 ± 0.284.77 ± 0.275.82 ± 0.53C22:6n-3 (docosahexaenoic acid)3.87 ± 0.334.18 ± 0.444.29 ± 0.254.23 ± 0.36Data are means ± standard errors. ^†^p \< 0.05 and ^††††^p \< 0.0001 for a maternal diet effect among the offspring of dams that received control gavage; \*\*p \< 0.01 for an effect of the gavage treatment between groups exposed to the same maternal diet.

Adult male offspring from the HF-FO group were no different from HF-Con in terms of food consumption, body weight (Fig. [2B](#Fig2){ref-type="fig"}), adiposity, or proportional liver weight (Table [4](#Tab4){ref-type="table"}). However, insulin sensitivity in the HF-FO group was greater than in the HF-Con group as indicated by higher Matsuda index (+85%; p = 0.014), lower HOMA-IR (−42%; p = 0.021), lower fasting insulin concentrations (−41%; p = 0.026), and a trend towards reduced insulin AUC (−35%; p = 0.052) (Table [5](#Tab5){ref-type="table"}). Of note, HF-FO indices of insulin sensitivity were similar to those in the Con-Con group (Table [5](#Tab5){ref-type="table"}) (p = 0.48 and p = 0.36 for Matsuda index and HOMA-IR, respectively). However, there were no differences in blood pressure, triglycerides, or leptin in adult male rats from HF-FO and HF-Con groups (Table [5](#Tab5){ref-type="table"}).

Effects of supplemental fish oil in control diet {#Sec12}
------------------------------------------------

There were no differences between the Con-FO and the Con-Con group in terms of food consumption, body weight, adiposity, insulin sensitivity, lipid profile, or systolic blood pressure (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). However, leptin levels were 2.6 times higher in adult Con-FO males (p = 0.027; Table [5](#Tab5){ref-type="table"}), an effect that remained after controlling for body fat percentage (p = 0.045).

Discussion {#Sec13}
==========

In this study, a rodent model of maternal high-fat feeding was used, which is known to induce maternal insulin resistance^[@CR18]^ and metabolic abnormalities in the offspring^[@CR16],\ [@CR18],\ [@CR20]^. As expected^[@CR16]--[@CR20]^, despite a standard postnatal diet the adult male offspring developed obesity associated with increased caloric intake, as well as reduced insulin sensitivity, increased plasma leptin and triglyceride levels, and higher systolic blood pressure. Importantly, maternal fish oil supplementation during pregnancy prevented the impairment of insulin sensitivity in the offspring. Given the established relationship between insulin sensitivity, type 2 diabetes mellitus, and the cardiovascular risk factors that make up the metabolic syndrome^[@CR15]^, supplementation with unoxidised fish oil during pregnancy could be a useful approach to reduce cardio-metabolic risk in the offspring of pregnancies complicated by obesity.

The intention of the fish oil treatment in pregnancy was to indirectly affect the developing pup by improving maternal insulin sensitivity, and therefore reducing excessive transfer of lipid and glucose to the fetus. While we were not able to demonstrate improved insulin sensitivity in the HF-FO dams, this does not indicate that the well-established insulin-sensitising effects of n-3 PUFAs in rodents^[@CR25],\ [@CR26]^ do not occur during pregnancy. The metabolic assessment of dams was conducted at the end of lactation, when the dams had continued to consume a high-fat diet, but had not been supplemented with fish oil for 21 days. Thus, potential insulin-sensitising effects of the fish oil treatment would be expected to be lost. Nevertheless, alternative mechanisms are possible. n-3 PUFAs are actively transported across the placenta^[@CR38]^, so that the n-3 PUFA rich supplement could have direct effects on fetal metabolism. For example, as n-3 PUFAs activate PPAR-γ^[@CR39]^, which is critical in adipogenesis^[@CR40]^, it is possible that n-3 PUFAs could have had an important effect on the developing adipose tissue in our study.

Fish oil supplementation in dams fed a control diet did not lead to any improvement in metabolic markers in the adult offspring. Unexpectedly, fasting leptin was elevated in the Con-FO group, even after adjustment for body fat. While hyperleptinaemia is considered unfavourable^[@CR41]^, it is not clear whether the increased leptin levels observed represent a primary increase in leptin secretion by adipose tissue, or a secondary increase due to leptin resistance. Pathological leptin resistance is unlikely since leptin has an important effect on appetite, and there were no differences in food consumption between groups. However, to determine whether there was subtle leptin resistance would require additional manipulations, such as assessing the effects of leptin injection on appetite suppression or response to a fasting challenge. Nevertheless, although there were no other adverse effects of fish oil supplementation, our study does not support any metabolic benefits of n-3 PUFA supplementation in the context of a maternal control diet, which models normal pregnancy.

While fish oil supplementation prevented the development of insulin resistance in the offspring of dams fed a high-fat diet, it did not prevent other adverse metabolic effects. This divergence of effects on insulin sensitivity and other metabolic parameters suggests that there are important differences in the programming of insulin sensitivity from other key aspects of the metabolic phenotype, specifically body composition, blood pressure, and leptin resistance.

One possible explanation for the lack of effect of the fish oil treatment on offspring outcomes (other than insulin sensitivity) could be that supplementation did not occur during lactation. In rats, a maternal high-fat diet, whether in pregnancy or solely during lactation, leads to greater adiposity and increased leptin, triglycerides, and blood pressure in the adult offspring^[@CR16],\ [@CR17]^. Thus, while fish oil ameliorated some of the adverse effects of a maternal high-fat diet during pregnancy, its effect during lactation could have been limited, as supplementation was solely during pregnancy and maternal stores would diminish over time. In this context, it was not surprising that HF-FO offspring displayed a phenotype of greater adiposity, increased leptin and triglyceride levels, and elevated systolic blood pressure compared to Con-Con offspring. We speculate that there would have been benefits of fish oil on energy balance, adiposity, triglycerides, and blood pressure if supplementation could have been continued throughout lactation.

As fish oil contains a range of fatty acids in addition to n-3 PUFAs, the potential effects of other fatty acids in the fish oil should also be considered. Taking into account both diet and supplement, the HF-FO dams consumed 17.5% more oleic acid than the HF-Con group (on day 19 of pregnancy), but intake of other fatty acids was similar. This did not affect the levels of oleic acid in tissue of the neonatal pups. The effects of changes in the intake of dietary oleic acid during pregnancy on the offspring are unknown. However, oleic acid-rich oils are commonly used as control treatments in metabolic studies^[@CR42]--[@CR44]^, and oleic acid does not activate the pathway that mediates the pro-adipogenic effects of n-6 PUFAs in pregnancy^[@CR24]^.

Interestingly, a maternal high-fat diet skewed the sex ratio in the offspring in favour of males, while sex ratio was unaffected by fish oil supplementation. Such skewing has been reported in previous rodent studies examining diets high in saturated fat^[@CR45],\ [@CR46]^, fructose^[@CR47]^, and salt^[@CR48]^, but the mechanism has not been elucidated.

The maternal high-fat diet model of developmental programming in rodents appears to be relevant to humans. Obesity, and in particular visceral obesity, is associated with adipose tissue inflammation^[@CR49],\ [@CR50]^, which leads to insulin resistance through abnormal adipokine secretion and free fatty acid release^[@CR51]^. Similarly, high-fat diets have been shown to increase inflammation of adipose tissue, through saturated fatty acids binding to toll-like receptor-4^[@CR52]^. Thus, the obese human condition and the obesogenic rat model are both characterized by adipose tissue inflammation and dysfunction. In addition, women who are obese and pregnant do tend to consume excess saturated fat^[@CR53]^.

In humans, studies investigating the effects of supplemental fish oil during pregnancy on offspring body composition or metabolism have yielded conflicting results in infancy and childhood^[@CR54]^ and no effect in young adults^[@CR55]^. However, these studies did not enrol women likely to have abnormally poor insulin sensitivity. As shown here, unoxidised fish oil supplementation in the context of the control diet (which modelled normal pregnancy) led to no metabolic improvements in the adult offspring. We speculate that that in obese human pregnancies (but not in normal pregnancies) supplementation with n-3 PUFAs (from pure concentrate or unoxidised fish oil) will lead to beneficial effects on body composition and metabolism of the offspring.

This study represents the first investigation into whether fish oil supplementation during pregnancy could prevent metabolic dysfunction in the offspring arising as a consequence of a maternal obesogenic environment. We focused on the metabolic phenotype of the offspring, and not the underlying mechanisms. This was because many of the assessments required to elucidate mechanism would likely affect offspring survival or metabolism (and thus confound the study), so that they would have to be conducted in parallel cohorts that would be culled after assessment (e.g. assessment of insulin sensitivity during pregnancy or collection of milk). However, having identified an important effect of fish oil supplementation on phenotype, such mechanistic studies should now be planned.

Our study has a number of limitations, primarily regarding the lack of data on mechanisms underpinning our observations. For example, as we did not assess maternal insulin sensitivity during pregnancy, we were not able to show whether fish oil supplementation improved maternal glucose metabolism during pregnancy. Similarly, as milk samples were not collected from rat dams, we could not determine whether pup development was influenced by possible changes in milk composition. Additional limitations include the focus on male offspring, and it is unclear if similar metabolic benefits would have been seen in female offspring. Further, as our rats were supplemented with fish oil and not a purified n-3 PUFA concentrate, it is possible that chemical components other than the n-3 PUFAs could have had important biological effects. Notably, there are two aspects of this study that are difficult to translate to humans. First, fish oil supplementation was started immediately after mating, and thus conception. In humans, the timing of conception is mostly unknown, so that starting supplementation at this point would be difficult to achieve, unless women intending to become pregnant took supplemental fish oil. Second, while the dose of fish oil used was similar to those of previous rodent studies^[@CR25]^, it is difficult to convert it to an equivalent human dose^[@CR56]^. Based on surface area, it equates to approximately 30 ml in humans, which would be unacceptable to many women. Further, women wishing to take an equivalent dose of n-3 PUFAs would be seriously hindered by their inability to access fresh unoxidised supplements such as the one used in this study.

Future studies using this model of maternal high-fat diet during pregnancy should specifically assess the effects of the n-3 PUFA intervention on a number of aspects: i) maternal glucose and lipid metabolism in pregnancy; ii) on milk quality; iii) whether there is additional benefit of supplementation with fish oil during lactation; iv) whether there are alterations in gene expression and epigenetic regulation in liver, skeletal muscle and adipose tissue; v) the phenotype of female offspring. Further, a specific assessment of leptin resistance should be used, to clarify the effect of fish oil supplementation in the context of normal pregnancy.

In summary, this study showed that unoxidised fish oil supplementation during pregnancy in rat dams who were fed a high-fat diet led to a long-term beneficial effect, preventing insulin resistance in adult offspring. Thus, if these findings are translated to humans, unoxidised n-3 PUFA rich oils could have a beneficial role in mitigating adverse metabolic programming in the offspring of women who are obese during pregnancy.
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